JP2008504266A - 異脂肪血症を治療するための化合物及び方法 - Google Patents

異脂肪血症を治療するための化合物及び方法 Download PDF

Info

Publication number
JP2008504266A
JP2008504266A JP2007518182A JP2007518182A JP2008504266A JP 2008504266 A JP2008504266 A JP 2008504266A JP 2007518182 A JP2007518182 A JP 2007518182A JP 2007518182 A JP2007518182 A JP 2007518182A JP 2008504266 A JP2008504266 A JP 2008504266A
Authority
JP
Japan
Prior art keywords
alkyl
trifluoromethyl
amino
dihydro
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007518182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008504266A5 (enExample
Inventor
アナ・マリア・エスクリバノ
マリア・カルメン・フェルナンデス
ネイサン・ブライアン・マントロ
アナ・イサベル・マテオ−エランス
エバ・マリア・マルティン・デ・ラ・ナバ
シャオドン・ワン
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008504266(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2008504266A publication Critical patent/JP2008504266A/ja
Publication of JP2008504266A5 publication Critical patent/JP2008504266A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2007518182A 2004-06-24 2005-06-22 異脂肪血症を治療するための化合物及び方法 Pending JP2008504266A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58270804P 2004-06-24 2004-06-24
US62724104P 2004-11-12 2004-11-12
US66486205P 2005-03-24 2005-03-24
PCT/US2005/021789 WO2006012093A1 (en) 2004-06-24 2005-06-22 Compounds and methods for treating dyslipidemia

Publications (2)

Publication Number Publication Date
JP2008504266A true JP2008504266A (ja) 2008-02-14
JP2008504266A5 JP2008504266A5 (enExample) 2008-08-07

Family

ID=35056992

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007518182A Pending JP2008504266A (ja) 2004-06-24 2005-06-22 異脂肪血症を治療するための化合物及び方法
JP2007518296A Expired - Fee Related JP4836945B2 (ja) 2004-06-24 2005-06-23 異常脂質血症を治療するための化合物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007518296A Expired - Fee Related JP4836945B2 (ja) 2004-06-24 2005-06-23 異常脂質血症を治療するための化合物および方法

Country Status (26)

Country Link
US (3) US20080269284A1 (enExample)
EP (3) EP1761521A1 (enExample)
JP (2) JP2008504266A (enExample)
KR (1) KR20070041452A (enExample)
CN (1) CN1972932B (enExample)
AT (1) ATE528304T1 (enExample)
AU (2) AU2005267436A1 (enExample)
BR (2) BRPI0512523A (enExample)
CA (2) CA2570688A1 (enExample)
CR (1) CR8831A (enExample)
CY (1) CY1112124T1 (enExample)
DK (1) DK1761522T3 (enExample)
EA (2) EA200700119A1 (enExample)
EC (2) ECSP067095A (enExample)
ES (1) ES2372291T3 (enExample)
HR (1) HRP20110761T1 (enExample)
IL (2) IL180277A (enExample)
MA (2) MA28729B1 (enExample)
MX (2) MXPA06014716A (enExample)
NO (2) NO20070468L (enExample)
NZ (1) NZ550978A (enExample)
PL (1) PL1761522T3 (enExample)
PT (1) PT1761522E (enExample)
RS (1) RS52064B (enExample)
SI (1) SI1761522T1 (enExample)
WO (2) WO2006012093A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
US20080269284A1 (en) 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
WO2007107843A1 (en) * 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2157190B1 (en) 2007-05-17 2017-05-03 EA Pharma Co., Ltd. Method of measuring the activity of lipid-modified enzyme
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013187406A1 (ja) * 2012-06-11 2013-12-19 アステラス製薬株式会社 4,4,7-トリフルオロ-1,2,3,4-テトラヒドロ-5h-1-ベンゾアゼピン化合物の製造方法及びその合成中間体
CN103958501B (zh) * 2012-07-16 2016-08-17 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
CN119499252A (zh) * 2014-02-05 2025-02-25 新阿姆斯特丹制药私人有限公司 用于治疗或预防心血管疾病的胆固醇酯转移蛋白抑制剂和含所述抑制剂的药物组合物
CN103833637B (zh) * 2014-03-31 2016-01-06 武汉武药制药有限公司 一种制备依塞曲匹（Evacetrapib）中间体的方法
WO2016198908A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
JP6549735B2 (ja) 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
BR112021002207A2 (pt) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
WO2024249901A2 (en) * 2023-06-01 2024-12-05 Nico Therapeutics, Inc. Compounds, compositions, and methods
CN117263810B (zh) * 2023-09-19 2026-01-27 上海凌凯科技股份有限公司 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法
CN117263966A (zh) * 2023-09-19 2023-12-22 上海凌凯医药科技有限公司 一种硼酸衍生物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095764A (ja) * 1998-09-17 2000-04-04 Pfizer Prod Inc 環化４―カルボキシアミノ―２―メチル―１，２，３，４―テトラヒドロキノリン
JP2002526476A (ja) * 1998-09-17 2002-08-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤としての４−アミノ置換−２−置換−１，２，３，４−テトラヒドロキノリン
WO2005095409A2 (en) * 2004-04-02 2005-10-13 Tanabe Seiyaku Co., Ltd. Tetrahydroquinoline derivatives and a process for preparing the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402506A1 (fr) * 1977-09-09 1979-04-06 Guelennec Emile Le Cisaille pour la decoupe de ferrailles de grandes dimensions
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5271716A1 (es) * 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CA2445623A1 (en) * 2001-04-30 2002-11-07 Pfizer Products Inc. Methods for preparing cetp inhibitors
US7332514B2 (en) 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
JP2006523218A (ja) 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
US20080269284A1 (en) 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095764A (ja) * 1998-09-17 2000-04-04 Pfizer Prod Inc 環化４―カルボキシアミノ―２―メチル―１，２，３，４―テトラヒドロキノリン
JP2002526476A (ja) * 1998-09-17 2002-08-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤としての４−アミノ置換−２−置換−１，２，３，４−テトラヒドロキノリン
WO2005095409A2 (en) * 2004-04-02 2005-10-13 Tanabe Seiyaku Co., Ltd. Tetrahydroquinoline derivatives and a process for preparing the same

Also Published As

Publication number Publication date
NZ550978A (en) 2010-08-27
CA2570673A1 (en) 2006-01-05
EP1761522A1 (en) 2007-03-14
EP2479175A1 (en) 2012-07-25
CN1972932A (zh) 2007-05-30
MXPA06014706A (es) 2007-03-12
EP1761522B1 (en) 2011-10-12
EA200700120A1 (ru) 2007-06-29
US20080269284A1 (en) 2008-10-30
NO20070468L (no) 2007-03-12
ECSP067095A (es) 2007-01-26
CR8831A (es) 2008-11-13
AU2005258241A1 (en) 2006-01-05
IL180277A (en) 2011-08-31
ES2372291T3 (es) 2012-01-18
SI1761522T1 (sl) 2012-02-29
KR20070041452A (ko) 2007-04-18
PT1761522E (pt) 2011-12-21
IL180277A0 (en) 2007-07-04
IL180276A0 (en) 2007-07-04
CY1112124T1 (el) 2015-11-04
US20070244095A1 (en) 2007-10-18
WO2006002342A1 (en) 2006-01-05
ATE528304T1 (de) 2011-10-15
EA012585B1 (ru) 2009-10-30
JP4836945B2 (ja) 2011-12-14
BRPI0512523A (pt) 2008-03-11
ECSP067098A (es) 2007-01-26
EP1761521A1 (en) 2007-03-14
MA28729B1 (fr) 2007-07-02
NO20070470L (no) 2007-03-26
US20100204207A1 (en) 2010-08-12
DK1761522T3 (da) 2012-01-02
JP2008504277A (ja) 2008-02-14
MXPA06014716A (es) 2007-03-12
CA2570673C (en) 2013-01-29
HRP20110761T1 (hr) 2011-11-30
CA2570688A1 (en) 2006-02-02
MA28730B1 (fr) 2007-07-02
CN1972932B (zh) 2011-06-29
PL1761522T3 (pl) 2012-03-30
BRPI0512516A (pt) 2008-03-11
AU2005258241B2 (en) 2011-08-25
WO2006012093A1 (en) 2006-02-02
AU2005267436A1 (en) 2006-02-02
EA200700119A1 (ru) 2007-10-26
RS52064B (sr) 2012-06-30
US7786108B2 (en) 2010-08-31
HK1104528A1 (en) 2008-01-18

Similar Documents

Publication Publication Date Title
KR20070041452A (ko) 이상지혈증 치료를 위한 화합물 및 방법
JP2007530550A (ja) 異脂肪血症を治療するための化合物および方法
CN105682656B (zh) 调节法尼醇x受体的组合物和方法
CA2828456C (en) N-benzl-amino-carboxamide inhibitors of the sodium channel
RU2158731C2 (ru) Производные ароилпиперидина или их соли, фармацевтический препарат на их основе и способ их получения
JP3218037B2 (ja) 喘息および呼吸器官の炎症の治療に有用なヘテロサイクリックアミン類
JP5209670B2 (ja) カリウムチャンネル機能のヘテロ環インヒビター
CN100402523C (zh) 杂环化合物及以其为有效成分的抗肿瘤药
JP2001519812A (ja) ソマトスタチン作動薬
WO2011007819A1 (ja) ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
JPH11501640A (ja) ５−ｈｔ▲下４▼拮抗作用を有するジ−置換１，４−ピペリジンエステル類及びアミド類
TW201623295A (zh) 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物
JPH08169884A (ja) シクロプロパクロメンカルボン酸誘導体
EP1019373A1 (fr) Nouveaux composes antagonistes selectifs du recepteur nk 3? humain, procede pour leur obtention et compositions pharmaceutiques les contenant
TW202239756A (zh) 作為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑硫羰基化合物及包含該等化合物之醫藥組合物
JP2005518375A (ja) Ｇタンパク質結合受容体（ｇｐｃｒ）のためのリガンドとしてのテトラヒドロカルバゾール誘導体
TW201522291A (zh) 胍基苯甲酸酯化合物
CA2841897A1 (en) Novel compound having parp inhibitory activity
KR100416674B1 (ko) 크로몬유도체
JPH07500604A (ja) 高血圧治療用エチルアラニンアミノジオール化合物
CN107840826B (zh) 1h-吲唑类衍生物及其作为ido抑制剂的用途
FR2824828A1 (fr) Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant
CN101434570B (zh) 吡咯烷衍生物及其制备方法和应用
JP2018519252A (ja) ファルネソイドｘ受容体をモジュレートするのに有用である縮合三環式ピラゾール誘導体
JP7449300B2 (ja) ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080619

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111122